Tyrosine News and Research

RSS

Combination of ibrutinib and rituximab shows promise against chronic lymphocytic leukemia

A two-prong approach combining ibrutinib and rituximab (Rituxin) to treat aggressive chronic lymphocytic leukemia (CLL) produced profound responses with minor side effects in a Phase 2 clinical trial at the University of Texas MD Anderson Cancer Center.

11 Dec 2012

RET fusion signals unique NSCLC subtype

The presence of RET fusion genes in approximately 1.5% of non-small-cell lung cancer defines a subset of tumors with distinct clinicopathologic features, research suggests.

10 Dec 2012

Ibrutinib may effectively combat chronic lymphocytic leukemia

The promising investigational targeted therapy ibrutinib and its mechanism of silencing gene communication pathways critical to the development of cancer may be an effective way to combat chronic lymphocytic leukemia (CLL), according to studies presented today at the 54th Annual Meeting of the American Society of Hematology (ASH).

10 Dec 2012

Targeting RAD52 protein can block the process by which leukemia stem cells repair themselves

Despite treatment with imatinib, a successful drug that targets chronic myeloid leukemia (CML), a deadly type of cancer, some patients may continue to be at risk for relapse because a tiny pool of stem cells is resistant to treatment and may even accumulate additional genetic aberrations, eventually leading to disease progression and relapse. These leukemia stem cells are full of genetic errors, loaded with potentially lethal breaks in DNA, and are in a state of constant self-repair.

10 Dec 2012

Bio-Path to initiate BP-100-1.01 Phase I trial for treatment of two types of breast cancer

Bio-Path Holdings, Inc., a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced it is initiating development of its lead cancer drug BP-100-1.01 (Liposomal Grb-2) to treat triple negative breast cancer (TNBC) and inflammatory breast cancer (IBC), two cancers characterized by formation of aggressive tumors and relatively high mortality rates.

6 Dec 2012

Tyk2 enzyme helps regulate obesity through differentiation of brown adipose tissue

Approximately 68 percent of U.S. adults are overweight or obese, according to the National Cancer Institute, which puts them at greater risk for developing cancer, cardiovascular disease, diabetes and a host of other chronic illnesses. But an international team of scientists led by Virginia Commonwealth University Massey Cancer Center researcher Andrew Larner, M.D., Ph.D., has successfully reversed obesity in mice by manipulating the production of an enzyme known as tyrosine-protein kinase-2 (Tyk2).

6 Dec 2012

Ponatinib offers new hope in drug-resistant leukemia

An investigational tyrosine kinase inhibitor, ponatinib, has shown high levels of activity in patients with chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.

5 Dec 2012

Researchers uncover molecular structure of master regulator central to melanoma

With the X-ray vision of DESY's light source DORIS, a research team from Hamburg and Iceland has uncovered the molecular structure of a master regulator central to the most deadly form of skin cancer, melanoma.

1 Dec 2012

Clinical trial shows effectiveness of ponatinib in patients with leukemia and lymphoma

Huntsman Cancer Institute researchers Michael Deininger, M.D., Ph.D., and Thomas O'Hare, Ph.D., were part of a team that found a potent oral drug, ponatinib, effective in patients who have developed resistance to standard treatments for chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic lymphoma.

30 Nov 2012

Lewy pathology out of favor as Parkinson’s culprit

Neurodegeneration and cellular dysfunction may precede the appearance of Lewy bodies in the substantia nigra, shows research that challenges the role of Lewy pathology in Parkinson’s disease.

30 Nov 2012

Exelixis announces FDA approval of COMETRIQ for treatment of medullary thyroid cancer

Exelixis, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved COMETRIQ (cabozantinib) for the treatment of progressive, metastatic medullary thyroid cancer (MTC).

30 Nov 2012

Ponatinib thwarts T315I gene mutation in chronic myeloid leukemia

A previously invincible mutation in chronic myeloid leukemia (CML) has been thwarted by an investigational drug in a phase I clinical trial reported in the current edition of The New England Journal of Medicine.

29 Nov 2012

Study shows how PTPN22 variant linked with T1D influences susceptibility to autoimmunity

As part of their ongoing research on the role of genes in the development of type 1 diabetes, Joslin Diabetes Center scientists, in collaboration with scientists at the University of Würzburg, have demonstrated how a genetic variant associated with type 1 diabetes and other autoimmune diseases influences susceptibility to autoimmunity. The findings appear in the upcoming issue of Diabetes.

29 Nov 2012

Tivantinib holds personalized therapy promise in HCC

Tivantinib is an effective second-line therapy for hepatocellular carcinoma patients whose tumors exhibit high MET receptor tyrosine kinase expression, indicate phase II study results.

26 Nov 2012

Acetylon's ective histone deacetylase inhibitors to be showcased at 54th ASH annual meeting

Acetylon Pharmaceuticals Inc., a leader in targeted epigenetic drug discovery and development for enhanced therapeutic outcomes, today announced that its selective histone deacetylase (HDAC) inhibitors will be featured in five posters and one oral presentation at the 54th Annual Meeting of the American Society of Hematology (ASH), taking place December 8-11, 2012, in Atlanta, Georgia.

21 Nov 2012

Study: Regular exercise before, during pregnancy could have beneficial effects for women

Contrary to popular thought, regular exercise before and during pregnancy could have beneficial effects for women that develop high blood pressure during gestation, human physiology professor Jeff Gilbert said, summarizing a new study by his research team that appears in the December issue of Hypertension, a journal of the American Heart Association.

16 Nov 2012

Scientists show how sorafenib can be dangerous to the heart

Scientists for the first time have evidence showing how a widely used type of "targeted" cancer drug can be dangerous to the heart.

7 Nov 2012

Taiho Pharmaceutical announces early stage data for eight novel oncology compounds

Taiho Pharmaceutical Co., Ltd., the developer of the first orally available fluorouracil (FU) Chemotherapeutic treatment (TS-1/S-1), is presenting early stage data for eight novel oncology compounds, including potential first-in-class therapies.

7 Nov 2012

Researchers unlock complex cellular mechanics that instruct glial progenitor cells to divide

In a new study appearing this month in the Journal of Neuroscience, researchers have unlocked the complex cellular mechanics that instruct specific brain cells to continue to divide. This discovery overcomes a significant technical hurdle to potential human stem cell therapies; ensuring that an abundant supply of cells is available to study and ultimately treat people with diseases.

2 Nov 2012

Nitisinone treatment effectively prevents tyrosinemia in children

A consortium of Quebec researchers coordinated by the Medical Genetics Service of the Sainte-Justine UHC has just published the findings of a 25-year study on the treatment of tyrosinemia, a life-threatening liver disease of genetic origin, which is screened at birth in the province of Quebec, where it is much more frequent than anywhere else in the world.

1 Nov 2012

Tyrosine News and Research

Combination of ibrutinib and rituximab shows promise against chronic lymphocytic leukemia

RET fusion signals unique NSCLC subtype

Ibrutinib may effectively combat chronic lymphocytic leukemia

Targeting RAD52 protein can block the process by which leukemia stem cells repair themselves

Bio-Path to initiate BP-100-1.01 Phase I trial for treatment of two types of breast cancer

Tyk2 enzyme helps regulate obesity through differentiation of brown adipose tissue

Ponatinib offers new hope in drug-resistant leukemia

Researchers uncover molecular structure of master regulator central to melanoma

Clinical trial shows effectiveness of ponatinib in patients with leukemia and lymphoma

Lewy pathology out of favor as Parkinson’s culprit

Exelixis announces FDA approval of COMETRIQ for treatment of medullary thyroid cancer

Ponatinib thwarts T315I gene mutation in chronic myeloid leukemia

Study shows how PTPN22 variant linked with T1D influences susceptibility to autoimmunity

Tivantinib holds personalized therapy promise in HCC

Acetylon's ective histone deacetylase inhibitors to be showcased at 54th ASH annual meeting

Study: Regular exercise before, during pregnancy could have beneficial effects for women

Scientists show how sorafenib can be dangerous to the heart

Taiho Pharmaceutical announces early stage data for eight novel oncology compounds

Researchers unlock complex cellular mechanics that instruct glial progenitor cells to divide

Nitisinone treatment effectively prevents tyrosinemia in children

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News